Table 3.
Outcome Characteristics
| Author | OS (in Months) | Systemic PFS (in Months) | Intracranial PFS | Criteria of Response | Complete/Partial Response (%) | Stable Disease (%) | Progressive Disease (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Steroids | No Steroids | Steroids | No Steroids | Steroids | No Steroids | Steroids | No Steroids | Steroids | No Steroids | Steroids | No Steroids | ||
| Studies included in meta-analysis | |||||||||||||
| Margolin et al. (2012) | 3.7 | 7 | 1.3 | 2.7 | 1.2 | 1.9 | irRC | 4.76 | 15.7 | 4.76 | 9.80 | 90.48 | 74.51 |
| Queirolo et al. (2014) | 2.9 | 4.9 | - | - | irRC | 8 | 12 | 8 | 16 | - | - | ||
| Chasset et al. (2015) | 4 | 7 | - | - | - | - | - | - | - | - | - | ||
| Jones et al.(2015) | 7 | 6 | - | - | - | - | - | - | - | - | - | ||
| Parakh et al. (2017) | 4.8 | 13.1 | - | - | 3.2 | 7.4 | - | - | - | - | - | - | - |
| Arbour et al. (2018) | 3.3 | 8.8 | - | - | - | - | - | - | - | - | - | ||
| Banks et al. (2019) | 5 | 5.9 | 1.8 | 1.9 | - | - | - | - | - | - | |||
| Galli et al. (2019) | 4 | 6 | 2.0 | 3.5 | - | - | - | - | - | - | - | ||
| Hendriks et al. (2019a) | 3.25 | 6.15 | 1.8 | 1.9 | - | - | - | - | - | - | - | ||
| Hendriks et al. (2019b) | - | - | - | - | Defined by investigator/local radiologist-assessed | - | - | 20 | 0 | 80 | 100 | ||
| Kotecha et al. (2019)a | 10.2 | 25.1 | - | - | RANO | 35 (≤60 mg) vs 23 (>60 mg) | 48 | 35.29 | - | 23 (≤60 mg) vs 18 (>60 mg) | 12 | ||
| Minniti et al. (2019) | 6 months: 91.2% 12 months: 57.3% |
6 months: 96% 12 months: 76.1% |
6 months: 42.3 12 months: 24.2 |
6 months: 73.6% 12 months: 35.9% |
- | - | - | - | - | - | - | ||
| Carron et al. (2020) | - | - | - | - | - | - | - | - | - | - | - | ||
| Zhang et al. (2020) | - | - | - | - | - | - | - | - | - | - | - | ||
| Studies not included in meta-analysis | |||||||||||||
| Dumenil et al. (2018) | - | - | - | - | RECIST 1.1 | 12.5 | 50 | 37.5 | 50 | 25 | 0 | ||
Abbreviations: irRC, immune-related response criteria; OS, overall survival; PFS, progression-free survival; RANO, Response Assessment in Neuro-Oncology Brain Metastases; RECIST 1.1, Response Evaluation Criteria in Solid Tumors.
- Not reported.
aTreatment response not used in the meta-analysis because of dichotomized outcomes.